CCM
TGTX icon

Camber Capital Management’s TG Therapeutics TGTX Stock Holding History

Camber Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000,000
Closed -$8.65M – 38
2019
Q2 		$8.65M Buy
+1,000,000
New +$7.56M 0.4% 28

Other funds holding TGTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Camber Capital Management's TGTX Position: Q3 2019 in Review

Camber Capital Management sold out of TG Therapeutics (TGTX) in Q3 2019, closing a stake of 1,000,000 shares — an estimated $8.65M sold.

Camber Capital Management first reported a position in TGTX in Q2 2019 and held it in 1 quarter. The position peaked at $8.65M in Q2 2019. 115 funds tracked by Wall St. Rank hold TGTX as of Q3 2019.

  • Camber Capital Management reported no remaining TG Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Camber Capital Management sold 1,000,000 TG Therapeutics shares in Q3 2019, an estimated $8.65M.
  • Camber Capital Management first reported a position in TG Therapeutics in Q2 2019 and held it in 1 quarter.
  • Camber Capital Management's TG Therapeutics position peaked at $8.65M in Q2 2019.
  • 115 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2019.

Based on Camber Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.